IFM launches subsidiary with $31M series A

IFM Therapeutics LLC (Boston, Mass.) launched inflammatory disease-focused subsidiary IFM Tre Inc. with a $31 million series A round co-led by Atlas Venture, Abingworth, Bristol-Myers Squibb Co. (NYSE:BMY) and IFM’s management.


Read the full 329 word article

How to gain access

Continue reading with a
two-week free trial.